Core Insights - Xu Ruihua, a professor at Sun Yat-sen University Cancer Prevention and Treatment Center, was elected as an academician of the Chinese Academy of Engineering for his work in developing immunotherapy and understanding gastrointestinal cancers [2][4] - Xu was also featured in Cell Press's "50 Scientists that Inspire" series, highlighting his contributions to cancer research and personalized treatment [2][4] Group 1: Scientific Innovation - Scientific innovation is a multi-dimensional process that involves not only the discovery of new knowledge but also the application of this knowledge to solve real-world problems [5][6] - Key dimensions of scientific innovation include meeting clinical needs, advancing scientific frontiers, and promoting interdisciplinary collaboration [6] - The future of cancer treatment is moving towards precision, personalization, and intelligence, emphasizing the importance of understanding molecular characteristics and biological mechanisms of tumors [6][9] Group 2: Personal Motivation and Challenges - Xu's initial motivation to become a scientist was to save lives, which was reinforced by his clinical experiences and the challenges faced by cancer patients [7][8] - The high incidence and mortality rates of gastrointestinal cancers in China, with 2 million new cases annually, drive Xu's commitment to finding effective treatments [7][8] Group 3: Research Achievements - A significant discovery was made regarding the benefit of immunotherapy for patients with MSI-H/dMMR advanced colorectal cancer, leading to a new treatment method combining HDAC inhibitors, immunotherapy, and anti-angiogenic drugs [8][9] - This research represents a clinical milestone and has the potential to redefine treatment models for advanced colorectal cancer [9] Group 4: Future Outlook - In the next 50 years, precision medicine is expected to dominate cancer treatment, with the integration of big data and artificial intelligence [12] - Immunotherapy will be applied to more cancer types, and liquid biopsy technology will mature, facilitating early detection and monitoring of cancer [12] - A multidisciplinary approach to cancer treatment will become standard, promoting global health through international collaboration [12]

Core Insights - A team from the University of Chicago has developed a more sensitive liquid biopsy technology that utilizes RNA instead of traditional DNA for cancer detection [1] - This innovative method achieved a 95% accuracy rate in identifying early-stage colorectal cancer using patient blood samples, significantly outperforming existing non-invasive detection methods [1] - The research was published in the latest issue of Nature Biotechnology [1]